EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

RegulatoryPositive

AI Analysis

Summary

EUDA announced that Shenzhen Inno received approval under the Shenzhen Key Industry R&D Program for TCR-T cell therapy development. This represents a routine regulatory recognition for the company's research initiatives.

Outcome Details

Approval under Shenzhen Key Industry R&D Program

Importance:3/10

Sentiment:

0.50

regulatory approvalR&D programTCR-T cell therapyChina

Related Companies

$EUDA

Read the original article

Published by yahoo_finance on April 28, 2026 10:00 AM

Read Original